- Home
- EICC vs KLTOW Comparison
EICC vs KLTOW Comparison
Compare EICC & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EICC | KLTOW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | EICC | KLTOW |
|---|---|---|
| Price | $25.06 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 31.7K | 9.8K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $51,224,692.00 | N/A |
| Revenue This Year | $39.61 | N/A |
| Revenue Next Year | $27.28 | N/A |
| P/E Ratio | $45.44 | ★ N/A |
| Revenue Growth | ★ 68.61 | N/A |
| 52 Week Low | $23.75 | $0.01 |
| 52 Week High | $25.84 | $0.95 |
Technical Indicators
Market Signals| Indicator | EICC | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 61.72 |
| Support Level | $25.05 | $0.10 |
| Resistance Level | $25.19 | $0.17 |
| Average True Range (ATR) | 0.06 | 0.01 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 3.25 | 83.00 |
Price Performance
Historical ComparisonAbout EICC Eagle Point Income Company Inc. 8.00% Series C Term Preferred Stock due 2029
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.